Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
https://www.zacks.com/stock/news/2193151/lilly-lly-gets-second-fda-nod-for-lymphoma-drug-jaypirca?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193151
Dec 04, 2023 - Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
0
ImmunoGen (IMGN) Gets FDA Priority Review for Elahere sBLA
https://www.zacks.com/stock/news/2194306/immunogen-imgn-gets-fda-priority-review-for-elahere-sbla?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2194306
Dec 06, 2023 - The FDA grants priority review to ImmunoGen's (IMGN) sBLA to convert the accelerated approval for Elahere to full approval for treating platinum-resistant ovarian cancer. A decision is due on Apr 5, 2024.
0
Top Stock Reports for AbbVie, NIKE & BHP
https://www.zacks.com/commentary/2194633/top-stock-reports-for-abbvie-nike-bhp?cid=CS-ZC-FT-research_daily-2194633
Dec 07, 2023 - Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), NIKE, Inc. (NKE) and BHP Group Ltd. (BHP).
0
Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod
https://www.zacks.com/stock/news/2195315/pharma-stock-roundup-abbv-to-buy-cere-jnj-s-2024-view-lly-nvs-get-fda-nod?cid=CS-ZC-FT-analyst_blog|stock_roundup-2195315
Dec 08, 2023 - AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.
0
AbbVie (ABBV) Declines More Than Market: Some Information for Investors
https://www.zacks.com/stock/news/2199022/abbvie-abbv-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2199022
Dec 15, 2023 - In the latest trading session, AbbVie (ABBV) closed at $154.04, marking a -0.54% move from the previous day.
0
3 Biotech Stocks Most Wall Street Analysts Are Bullish About
https://www.zacks.com/stock/news/2199324/3-biotech-stocks-most-wall-street-analysts-are-bullish-about?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199324
Dec 18, 2023 - Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.
0
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B
https://www.zacks.com/stock/news/2201667/bristol-myers-bmy-to-buy-karuna-therapeutics-for-14b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201667
Dec 22, 2023 - Bristol Myers (BMY) announces a second acquisition in two months. It is set to buy Karuna Therapeutics, Inc. (KRTX) for $14 billion to strengthen its neuroscience portfolio.
0
Pharma Stock Roundup: LLY's New Digital Pharmacy, NVO & ABBV's Fresh R&D Deals
https://www.zacks.com/stock/news/2206363/pharma-stock-roundup-lly-s-new-digital-pharmacy-nvo-abbv-s-fresh-r-d-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-2206363
Jan 05, 2024 - Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two research collaborations to develop novel treatments for cardiometabolic diseases.
0
Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report?
https://www.zacks.com/stock/news/2206449/will-abbvie-abbv-beat-estimates-again-in-its-next-earnings-report?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2206449
Jan 05, 2024 - AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
0
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
https://www.zacks.com/stock/news/2208771/want-better-returns-don-t-ignore-these-2-medical-stocks-set-to-beat-earnings?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2208771
Jan 11, 2024 - Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
0